When was NEUROPATHIX founded?

NEUROPATHIX was founded in 2010 and raised its 1st funding round 11 years after it was founded.

Where is NEUROPATHIX located?

NEUROPATHIX is headquartered in Doylestown, United States.

How many employees does NEUROPATHIX have?

As of Mar 31, 2026, the latest employee count at NEUROPATHIX is 3.

Is NEUROPATHIX a funded company?

NEUROPATHIX is a funded company, having raised a total of $***** in its 1st and only funding round, a Post IPO round on Feb 23, 2021.

When was the latest funding round of NEUROPATHIX?

NEUROPATHIX's latest funding was a $***** Post IPO round on Feb 23, 2021, with participation from 0 investor.

What is the annual revenue of NEUROPATHIX?

Annual revenue of NEUROPATHIX is $126K as on Dec 31, 2019.

Where does NEUROPATHIX rank among its competitors?

NEUROPATHIX ranks 7th amongst 23 active competitors, of which 3 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was SciSparc, which secured $4.2M in Feb, 2025.

Who are the top competitors of NEUROPATHIX?

NEUROPATHIX's top competitors include IGC Pharma, GW Pharma and MIRA Pharmaceuticals. Among them, SciSparc secured the most recent funding round in February, 2025.

NEUROPATHIX - 2026 Company Profile, Team, Funding, Competitors & Financials

NEUROPATHIX is a public company based in Doylestown (United States), founded in 2010 by Thoma Kikis. It operates as a Developer of therapeutics targeting inflammation, neurodegeneration, oxidative stress, and neuropathic pain. NEUROPATHIX has raised an undisclosed amount in funding. The company has 23 active competitors, including 3 funded and 7 that have exited. Its top competitors include companies like IGC Pharma, GW Pharma and MIRA Pharmaceuticals.

Company Details

Developer of therapeutics targeting inflammation, neurodegeneration, oxidative stress, and neuropathic pain. The company focuses on researching and developing a product platform of molecules. It conducts preclinical drug discovery and development of synthetic cannabidiol-inspired therapeutics. The company’s subsidiary holds a license for the commercialization of a U.S. government patent.

Website: neuropathix.com
Social
Email ID: *****@neuropathix.com
Phone Number: +1 **********

Key Metrics

Founded Year

2010

Location

Doylestown, United States

Stage

Public

Latest Funding Round

Post IPO, Feb 23, 2021, $*****

Ranked

7^th among 23 active competitors

Annual Revenue

$126K as on Dec 31, 2019

Employee Count

3 as on Mar 31, 2026

Similar Companies

IGC Pharma & 24 more

Exit Details

Public

View NEUROPATHIX's full profile

NEUROPATHIX is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
TYG SOLUTIONS CORP. CIN: 1615999 , United States, Active		$126K (As on Dec 31, 2019)	7 (As on Dec 31, 2020)	-
NEUROPATHIX INC. CIN: 5308872 , United States, Active	Mar 24, 2013	$183K (As on Dec 31, 2021)	-	-

NEUROPATHIX got listed on Dec 05, 2019.

Click here to take a look at NEUROPATHIX's IPO in detail

NEUROPATHIX has raised funding over 1 round.

Here is the list of recent funding rounds of NEUROPATHIX:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 23, 2021	7648600	Post IPO	2986721	5890794	9479225	2742877

Access funding benchmarks and valuations. Sign up today!

View details of NEUROPATHIX's funding rounds and investors

The founders of NEUROPATHIX is Thoma Kikis. Dean Petkanas is the CEO of NEUROPATHIX.

Here are the details of NEUROPATHIX's key team members:

Thoma Kikis: Founder of NEUROPATHIX.
Contact Info: 1 email address
Dean Petkanas: CEO of NEUROPATHIX.
Contact Info: 2 email addresses

View details of NEUROPATHIX's Founder profiles and Board Members

NEUROPATHIX's employee count trend

NEUROPATHIX has 3 employees as of Mar 26. Here is NEUROPATHIX's employee count trend over the years:

Uncover NEUROPATHIX's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of NEUROPATHIX include IGC Pharma, GW Pharma and MIRA Pharmaceuticals. Here is the list of Top 10 competitors of NEUROPATHIX, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	IGC Pharma 2005, Potomac (United States), Public	Developer of therapies and artificial intelligence tools for Alzheimer’s disease	-	BRADBURY, Bradbury Group	59/100
2nd	GW Pharma 1998, Cambridge (United Kingdom), Acquired	Developer of cannabinoid medicines for MS spasticity, cancer pain and childhood epilepsy	$46.5M	New Leaf Capital, Bondeinvest.com & 6 others	50/100
3rd	MIRA Pharmaceuticals 2020, Baltimore (United States), Public	Developer of cannabinoid-based therapeutics for chronic pain and anxiety	-	-	50/100
4th	Hyasynth Bio 2014, Montreal (Canada), Series A	Developer of cannabinoid products intended to treat neurological disorders	$11M	Organigram, Anges Quebec & 10 others	47/100
5th	SciSparc 2004, United States, Public	Developer of cannabinoid technologies for central nervous system disorder treatments	-	-	45/100
6th	Avata Biosciences 2023, New York City (United States), Unfunded	Developer of cannabinoid medicines for neurological diseases	-	-	40/100
7th	NEUROPATHIX 2010, Doylestown (United States), Public	Developer of therapeutics targeting inflammation, neurodegeneration, oxidative stress, and neuropathic pain	-	-	33/100
8th	Cannformatics 2017, San Francisco (United States), Unfunded	Developer of personalized medical cannabis treatment	-	-	38/100
9th	Neurotech International 2016, Perth (Australia), Public	Developer of therapeutics for multiple paediatric neurological disorders	-	Transcontinental Group	37/100
10th	Pike Therapeutics 2019, Vancouver (Canada), Series A	Developer of psychedelic and cannabinoid therapeutics	$4.09M	-	34/100